The Faces Behind TauRx

“No good ever came out of rushing… I adhere to this golden rule.”
– Dr K M Seng, TauRx Co-Founder and Visionary Venture Capitalist, Singapore

The quest to find an effective therapeutic approach aimed at halting the progression of Alzheimer’s has been a lifelong dedication of many TauRx team members. These are scientists and researchers who have significantly enhanced the world’s understanding of Tau pathology. Importantly, their pioneering work has spearheaded the development of Tau Aggregation Inhibitors for Alzheimer’s and other neurodegenerative disorders.


Charles Harrington, PhD (TauRx Chief Scientific Officer)

Charlie Harrington1Dr Harrington leads the biological research team at the University of Aberdeen that is supporting TauRx’s work. He has extensive research experience in the field of neurodegenerative diseases, particularly in Alzheimer’s, having authored more than 50 publications and co-invented 8 patent applications in the field. Dr. Harrington has collaborated with Professor Wischik for over 20 years, previously while at the Cambridge Brain Bank Laboratory and later as a Senior Research Fellow in the Institute of Medical Sciences at the University of Aberdeen. During this period, Professor Wischik, Dr Harrington and colleagues developed assays for screening agents having the potential to prevent the Tau pathology that is a hallmark of Alzheimer’s. They built upon these assays to create the platform technology at TauRx, one on the most sophisticated and extensive Tau directed platforms currently available. Previously, Dr Harrington was a fellow in Professor Sir James Baddiley’s laboratory in the Department of Biochemistry at the University of Cambridge.


John Storey, PhD (TauRx Head Chemist)

Faces_Storey_JohnProfessor Storey leads the team of chemists at the University of Aberdeen who have synthesised TauRx’s portfolio of drug candidates. He is responsible for their chemical scale-up, analysis, encapsulation and formulation. Professor Storey holds the position of Chair of Pharmaceutical Industrial Chemistry at the University of Aberdeen, and he has collaborated with TauRx for 8 years. He was previously senior lecturer in pharmaceutical science at Kingston University. Professor Storey has published chapters in mechanistic organic chemistry books and reviews on radical chemistry and individual publications in the area of chemical synthesis and radical chemistry. He is a co-inventor of 10 patents pending with TauRx.


Sir Martin Roth (1917-2006)

“We must find a way to strangle the tangle.”

Faces_Roth_SirMartinMartin Roth is well-known for his contributions to psychiatry. His philosophy was “research based, intellectually rigorous, and compassionate”, according to the Royal College of Psychiatrists. He taught a generation of psychiatrists and was a source of inspiration for mental health research. In Cambridge he pursued these studies with the MRC Neurochemistry and Neuropharmacology Unit and with the Molecular Biology Laboratory and its Nobel laureate director, Sir Aaron Klug. At Cambridge, he produced a series of papers on the abnormal protein, called Tau, found in the brains of patients with Alzheimer's disease and oversaw the work of Claude Wischik, who was unraveling the role of Tau protein in Alzheimer’s disease.


Dr K.M. Seng

Faces_Seng_KMA gynecologist, surgeon and visionary venture capitalist from Singapore who co-founded TauRx with Professor Claude Wischik. Their sons were classmates and his son follows in his footsteps as Managing Director of TauRx.




Dr Alois Alzheimer (1864-1915)

Faces_Alzheimer_AloisIn 1906, the German neuropsychiatrist Alois Alzheimer was the first to make certain observations during the post-mortem study of a woman who had had dementia. He noted deposits, or ‘plaques’, of what he called ‘a peculiar substance’ scattered all over the brain, and ‘dense bundles’, or tangles, of fibrils within brain cells, many of which had died. The plaques, which had been discovered by Blocque and Marinesco in 1982, seemed to be part of normal aging, but the tangles seemed to have a much closer link to dementia. Later, the disease was named after Dr. Alzheimer.

“Excessive reservations and paralyzing despondency have not helped the sciences to advance nor are they helping them to advance, but a healthy optimism that cheerfully searches for new ways to understand, as it is convinced that it will be possible to find them.” --Alois Alzheimer’s research motto


TauRx Publishes Six New Journal Articles

TauRx Completes Recruitment to Phase 3 Alzheimer’s Disease Studies